179 related articles for article (PubMed ID: 22960937)
1. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
[TBL] [Abstract][Full Text] [Related]
2. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
J Thorac Oncol; 2012 Jan; 7(1):249-56. PubMed ID: 22031231
[TBL] [Abstract][Full Text] [Related]
3. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
4. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
8. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
10. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
Ting S; Mairinger FD; Hager T; Welter S; Eberhardt WE; Wohlschlaeger J; Schmid KW; Christoph DC
Clin Lung Cancer; 2013 Sep; 14(5):558-567.e3. PubMed ID: 23810210
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
[TBL] [Abstract][Full Text] [Related]
12. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
13. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
Zimling ZG; Santoni-Rugiu E; Bech C; Sørensen JB
Anticancer Res; 2015 Dec; 35(12):6731-8. PubMed ID: 26637889
[TBL] [Abstract][Full Text] [Related]
14. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
Vilmar AC; Santoni-Rugiu E; Sørensen JB
Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
[TBL] [Abstract][Full Text] [Related]
15. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
Sève P; Lai R; Ding K; Winton T; Butts C; Mackey J; Dumontet C; Dabbagh L; Aviel-Ronen S; Seymour L; Whitehead M; Tsao MS; Shepherd FA; Reiman T
Clin Cancer Res; 2007 Feb; 13(3):994-9. PubMed ID: 17289895
[TBL] [Abstract][Full Text] [Related]
16. Measuring β-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer.
Chen X; Wu J; Lu H; Huang O; Shen K
Cancer Sci; 2012 Feb; 103(2):262-8. PubMed ID: 22035021
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Zhang L; Liu T; Zhang JQ
Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):212-6. PubMed ID: 21575522
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
Stebbing J; Powles T; McPherson K; Shamash J; Wells P; Sheaff MT; Slater S; Rudd RM; Fennell D; Steele JP
Lung Cancer; 2009 Jan; 63(1):94-7. PubMed ID: 18486273
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]